Clinical Trial Update: Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating niraparib and bevacizumab as maintenance therapy in platinum-sensitive recurrent ovarian cancer patients previously treated with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platinum-sensitive Recurrent Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Niraparib (Niraparib)

Snippet

Sponsor: Yonsei University | Conditions: Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor | Phase 2 | Status: UNKNOWN